Cargando…
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however,...
Autores principales: | Elbezanti, Weam Othman, Challagundla, Kishore B., Jonnalagadda, Subash C., Budak-Alpdogan, Tulin, Pandey, Manoj K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056051/ https://www.ncbi.nlm.nih.gov/pubmed/36986514 http://dx.doi.org/10.3390/ph16030415 |
Ejemplares similares
-
Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021) -
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2021) -
Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells
por: Elbezanti, Weam Othman, et al.
Publicado: (2022) -
Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2022) -
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021)